Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CBWletoF.js ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB. Type a few ...

Mizuho raised the firm’s price target on Sage Therapeutics (SAGE) to $9 from $6 and keeps a Neutral rating on the shares. The firm reassessed ...

Truist has initiated coverage of Larimar (LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

The stock's fall snapped a five-day winning streak.

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...